| 22-Jan-18 | Bioverativ Inc | $11,600 | Sanofi will acquire all of the outstanding shares of Bioverativ and also expand Expands Sanofi’s presence in specialty care and strengthens leadership in rare diseases Adds leader in the growing hemophilia market and provides platform for expansion in other rare blood disorders Drives meaningful shareholder value with ROIC expected to exceed cost of capital within three years Enhances Sanofi’s sustainable revenue and earnings growth. Provides immediate Business EPS accretion. | Sanofi | Acquisition | United States |
| 22-Jan-18 | Juno Therapeutics Inc | $9,000 | Juno is a pioneer in the development of CAR (chimeric antigen receptor) T and TCR (T cell receptor) therapeutics with a broad, novel portfolio evaluating multiple targets and cancer indications. Adding to Celgene's lymphoma program, JCAR017 (lisocabtagene maraleucel; liso-cel) represents a potentially best-in-class CD19-directed CAR T currently in a pivotal program for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). | Celgene Corporation | Acquisition | United States |
| 07-Jan-18 | Impact Biomedicines | $7,000 | Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Based on the reported benefit risk profile of fedratinib from the JAKARTA-1 and JAKARTA-2 clinical trials, regulatory applications in myelofibrosis are planned beginning in the middle of 2018. | Celgene Corporation | Acquisition | United States |
| 29-Jan-18 | Ablynx | $4,800 | To advance the strategic transformation of Research and Development, expanding our late-stage pipeline and strengthening platform for growth in rare blood disorders. This acquisition builds on a successful existing partnership, pleased to reaffirm our commitment to Belgium, where the company invested significantly over the years in our state-of-the-art biologics manufacturing facility in Geel. | Sanofi | Acquisition | Belgium |
| 08-Jan-18 | Regeneron | $1,640 | To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs | Sanofi | Expansion | United States |
| 30-Jan-18 | Sirtex Medical Limited | $1,283 | This acquisition of a global leader in radioembolization extends Varian's leadership in radiation medicine, expands Varian's addressable market into interventional oncology, and is consistent with Varian's long-term growth and value creation strategy. Varian expects to leverage its capabilities in treatment planning and delivery, image guidance and processing, oncology practice management software, and radiation safety in combination with Sirtex's interventional oncology platform to provide | Varian Medical Systems | Acquisition | Australia |
| 04-Jan-18 | Arvinas | $830 | For the discovery and development of drug candidates using Arvinas’ proprietary PROTAC (PROteolysis TArgeting Chimeras) Platform, a novel technology used to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. | Pfizer Inc. | Licensing Agreement | United States |
| 31-Jan-18 | Cascadian Therapeutics | $614 | Enhances Seattle Genetics’ Portfolio of Solid Tumor Programs with Potential Rapid Registrational Pathways | Seattle Genetics | Acquisition | United States |
| 04-Jan-18 | MacroGenics | $380 | MacroGenics had entered into a research collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to jointly discover and develop novel bispecific molecules to undisclosed targets. During the research term, both companies will leverage their respective platforms, including MacroGenics' DART® platform and Roche's CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate. | Roche | Research Agreement | United States |
| 03-Jan-18 | Addex Pharma | $330 | The collaboration includes an exclusive global license to lead candidate ADX71441, which is a novel, first-in-class, oral, small molecule and is expected to enter Phase 1 trials in 2018. The collaboration also includes exclusive global license to backup GABAB PAM compounds, as well as a research collaboration focused on discovering additional GABAB PAMs. | Indivior PLC | Collaboration | Switzerland |
| 03-Jan-18 | Boehringer Ingelheim Venture Fund (BIVF) | $300 | To invest in promising early stage start-up companies, focusing on regenerative medicine, infectious diseases and immune oncology among others, as well as growing the portfolio in the U.S. and opening doors for the BIVF in digital health | Boehringer Ingelheim | Series A Financing | Germany |
| 08-Jan-18 | CardioSert Ltd | $300 | To Acquire Novel Technology to Enhance Existing Technology Platforms and Strengthen Patent Portfolio | Microbot Medical Inc | Acquisition | United States |
| 04-Jan-18 | BioNTech AG | $270 | To advance its clinical pipeline of individualized immunotherapies covering a number of new approaches including mRNA and CAR-T / T-Cell receptors for the treatment of cancer and other diseases with high medical need | Redmile Group | Series A Financing | Germany |
| 08-Jan-18 | RegenXBio | $260 | The Development and Commercialization of Treatments for Spinal Muscular Atrophy | AveXis | Licensing Agreement | United States |
| 24-Jan-18 | Mitobridge Inc | $225 | The transaction accelerates Astellas’ research and development in diseases associated with mitochondrial dysfunctions and will enable the delivery of innovative new treatment options to patients | Astellas Pharma | Acquisition | United States |
| 05-Jan-18 | Jiangsu Hengrui Medicine | $223 | Development and Commercialization Partnership for Novel Immune-Mediated Dermatology Therapy Using SHR0302, for the treatment of dermatology disorder | Arcutis Inc | Licensing Agreement | China |
| 25-Jan-18 | Karyopharm Therapeutics Inc | $217 | To acquire Karyopharm’s investigational oral SINE compound KPT-350 and other assets for the treatment of certain neurological and neurodegenerative conditions. | Biogen | Acquisition | United States |
| 30-Jan-18 | Neomed Institute | $202 | To advance NEOMED's NEO1940 novel, peripherally restricted, CB1/CB2 agonist, clinic-ready drug candidate for the treatment of patients suffering from cancer and anorexia/weight loss associated with cancer | Artelo Biosciences | Licensing Agreement | Canada |
| 08-Jan-18 | Teva Pharmaceuticals | $200 | To develop, manufacture and commercialize eptinezumab in the U.S. and worldwide, excluding Japan and Korea | Alder BioPharmaceuticals | Licensing Agreement | Germany |
| 24-Jan-18 | Spark Therapeutics | $170 | To develop and commercialize investigational voretigene neparvovec outside the U.S. | Novartis | Licensing Agreement | United States |
| 09-Jan-18 | Adapsyn Bioscience | $162 | To Advance its Small Molecule Natural Product Platform and Pipeline; Announces Research Collaboration with Pfizer | Pfizer Inc. | Collaboration | Canada |
| 09-Jan-18 | Mallinckrodt plc | $153 | To Broaden Portfolio of Innovative Surgical Products | Baxter | Acquisition | United Kingdom |
| 05-Jan-18 | Denali Therapeutics | $240 | To Develop and Commercialize Therapies for Neurodegenerative Diseases | Takeda Pharmaceutical Company | Collaboration | United States |
| 31-Jan-18 | STAT-Dx | $147 | To launch a next-generation, fully integrated multiplex platform for syndromic disease testing | QIAGEN N.V. | Acquisition | United States |
| 23-Jan-18 | Gilead Sciences, Santa Monica | $135 | Under contract to buy the 160,000-square-foot flex building at 1800 Stewart St. from Agensys, Inc., a biotechnology and cancer-research company owned by Tokyo’s Astellas Pharma, Inc. | Gilead Sciences | Investment | United States |
| 23-Jan-18 | Tmunity Therapeutics | $100 | To Advance Portfolio of Next-Generation T cell Immunotherapies to Transform the Treatment of Cancer | Gilead Sciences | Series A Financing | United States |
| 04-Jan-18 | Receptos Inc | $100 | Focused on Discovering and Developing a Pipeline of Novel and Differentiated Drug Candidates | Omega Funds Venture Partners and | Series A Financing | United States |
| 04-Jan-18 | KBP Biosciences | $76 | Established China Biotechnology Company with Deep R&D Pipeline,Proceeds will also advance clinical development of lead candidate, KBP-5074, through Phase 2b trials for cardiovascular disease | Advantech Capital and SDIC Venture Capital etc | Series A Financing | United States |
| 22-Jan-18 | Data Sciences International Inc | $70 | To acquire 100% of the outstanding stock | Harvard Bioscience Inc | Acquisition | United States |
| 02-Jan-18 | Centrexion Therapeutics | $67 | The proceeds will be used to fund the Phase 3 program for Centrexion’s lead therapy, CNTX-4975, a synthetic, ultra-pure injection of trans-capsaicin, for the treatment of chronic pain due to knee osteoarthritis (OA) | New Enterprise Associates | Series D Financing | United States |
| 02-Jan-18 | QED Therapeutics | $65 | To Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics | BridgeBio Pharma | Licensing Agreement | United States |
| 22-Jan-18 | Eureka Therapeutics | $60 | To Advance Proprietary ARTEMIS™ T Cell Receptor Platform For Safer T Cell Therapies | Acorn Pacific Ventures | Series D Financing | United States |
| 18-Jan-18 | Pandion Therapeutics | $58 | To Advance Tissue-Specific Immune Modulator Drugs for Autoimmune and Inflammatory Diseases | Versant Ventures and Roche Venture Fund SR One and BioInnovation Capital | Series A Financing | United States |
| 07-Jan-18 | Alnylam Pharmaceuticals Inc | $50 | Enables Streamlined Development and Optimization of Commercial Opportunities for ATTR Amyloidosis and Hemophilia Programs | Sanofi | Partnership | United States |
| 03-Jan-18 | Scholar Rock Holding | $47 | To Advance Innovative Pipeline for SMA, Immuno-Oncology, Fibrosis, and Iron-Restricted Anemias | Redmile Group | Series C Financing | United States |
| 04-Jan-18 | Neurogastrx Inc | $45 | To fill out the management team and reach proof of concept with its lead asset, NG-101, which is intended to treat gastroparesis, a debilitating functional GI disorder | 5AM Ventures | Series A Financing | United States |
| 04-Jan-18 | Stoke Therapeutics | $40 | To support the further advancement of multiple pre-clinical development programs | Apple Tree Partners | Series A Financing | United States |
| 03-Jan-18 | Elstar Therapeutics | $39 | To Support Development of its Universal Targeted Immunotherapy Platform (UniTITM) | Apple Tree Partners | Series A Financing | United States |
| 04-Jan-18 | Enterome | $39 | To treat microbiome-associated diseases with a focus on inflammatory bowel diseases (IBD) and immuno-oncology (IO) indications | Seventure, Health for Life Capital, Lundbeck Fonden Ventures, Omnes Capital & Nestle Health Science | Series D Financing | France |
| 23-Jan-18 | Bonti | $16 | To continue developing EB-001, a unique botulinum neurotoxin, for its targeted therapeutic and aesthetic indications with significant addressable unmet needs in patients | Unknown | Investment | United States |
| 05-Jan-18 | Alliqua Biomedical | $29 | Celularity will acquire all of the property, assets and rights relating to the Company’s advanced biologic wound care business - including Biovance® amniotic membrane allograft and Interfyl® Human Connective Tissue Matrix - and the Company’s UltraMist® | Celularity | Purchase Agreement | United States |
| 30-Jan-18 | Corbus Pharmaceuticals | $25 | To Support Phase 2b Clinical Study of Lenabasum | Cystic Fibrosis Foundation | Development Agreement | United States |
| 02-Jan-18 | Inovio Pharmaceuticals | $43 | This collaboration of VGX-3100 encompasses the treatment and/or prevention of precancerous HPV infections and HPV-driven dysplasias (including cervical, vulvar and anal precancers) and excludes HPV-driven cancers and all combinations of VGX-3100 with other immunostimulants. The agreement also provides for potential inclusion of the Republic of Korea during the next three years. | ApolloBio Corp. | Licensing Agreement | United States |
| 01-Jan-18 | NexImmune | $23 | To Advance Endogenous Cellular ImmunoTherapy into Clinical Development | ArrowMark Partners and Barer & Son Capital | Series A Financing | United States |
| 04-Jan-18 | Oculis | $20 | The funds will be used to advance the clinical development of the Company's lead program OC-118, a proprietary topical product currently in a Phase IIb clinical trial for the treatment of Diabetic Macular Edema (DME) | Novartis | Series B Financing | Switzerland |
| 11-Jan-18 | KWS BioTest | $20 | The addition of KWS BioTest’s world-leading immunology expertise makes additional tools available in the increasingly active and promising therapeutic research areas of immunology, oncology, and autoimmune and infectious disease. | Charles River | Acquisition | United Kingdom |
| 17-Jan-18 | Enochian Biopharma | $20 | Enochian's technology will enhance DanDrit's research and development efforts in cellular therapy and add to its pipeline, which also includes cellular immuneoncology products for the prevention of relapse of metastatic colon cancer after resection and chemotherap | DanDrit Biotech USA | Acquisition | United States |
| 10-Jan-18 | PharmaIN Corporation | $17 | PharmaIN which has innovative platform technologies for drug discovery of various molecules including peptides, proteins and small molecules | Shionogi & Co., Ltd. | Collaboration | United States |
| 09-Jan-18 | BIAL | $16 | For the importation, packaging and commercialization of Opicapone in China (excluding Hong Kong, Macao and Taiwan). | Shanghai Fosun Pharmaceutical Group | Licensing Agreement | Portugal |
| 09-Jan-18 | Carmot Therapeutics | $15 | The funds will support development of the company’s lead type 2 diabetes drug, a dual GLP-1R/GIPR agonist, through early clinical proof of concept | Horizons Ventures | Series B Financing | United States |
| 16-Jan-18 | OWKIN | $13 | Funding will expand OWKIN Socrates, the first data driven discovery platform for clinical research | Otium Venture | Series A Financing | United States |
| 30-Jan-18 | Dosecann Inc | $9 | Dosecann investment to leverage existing synergies within MMJ portfolio | MMJ PhytoTech Limited | Acquisition | Canada |
| 16-Jan-18 | Pherecydes Pharma | $10 | To produce phages for compassionate use (ATU or Temporary Authorization for Use) in accordance with GMP. Pherecydes will move two programs into the clinical phase in 2018 and 2019 | Omnes Capital etc | Series B Financing | France |
| 17-Jan-18 | Pisgah Labs Inc | $10 | Acquisition of 100% share capital of Pisgah Labs Inc North Carolina. USA by Company's subsidiaries | Ipca Pharmaceutical Inc, USA (subs Onyx Scientific Ltd) | Acquisition | United States |
| 23-Jan-18 | Skyhawk Therapeutics, Inc | $8 | To Advance Its Novel Platform and Portfolio of Small Molecules That Correct RNA Expression | Alexandria Venture Investments | Seed Financing | United States |
| 23-Jan-18 | GT Biopharma Inc | $7 | To advance its immuno-oncology programs, which are based on the company's proprietary Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs™ and TetraKEs) and bispecific antibody-drug conjugate (ADC) platforms, neurology (CNS) pipeline progress, and for general corporate purposes | Oppenheimer Holdings | Financing | United States |
| 02-Jan-18 | Piedmont Pharmaceuticals LLC | $7 | Acquires Global ex-U.S. Product Rights and existing Royalty Streams to Resultz® | Nuvo Pharmaceuticals Inc., Deerfield Management Company | Acquisition | United States |
| 29-Jan-18 | Cellect Biotechnology | $4 | Company will issue 484,848 registered American Depository Shares (ADSs) at a purchase price of $8.25 per ADS in a registered direct offering. | HC Wainwright & Co | IPO | Israel |
| 08-Jan-18 | Level Brands Inc | $2 | To develop consumer products for kathy ireland® Health & Wellness, a licensor to Level Brands, and for Level Brands subsidiary I’M1, the company’s lifestyle brand for men | Isodiol International Inc | Licensing Agreement | United States |
| 16-Jan-18 | Metrion Biosciences | $1 | Industry-leading ion channel | SyndicateRoom | Investment | United Kingdom |
| 18-Jan-18 | Serum Institute of India Pvt Ltd | $0 | To manufacture & sell fully liquid Whole cell Pertussis (wP) and Salk based Injectable Polio Vaccine (IPV) based Hexavalent vaccine (DTwP-HepB-Hib-IPV) | Panacea Biotec Ltd | Collaboration | India |
| 29-Jan-18 | FDA | $0 | Regarding the design of its next study of lenabasum (formerly known as anabasum),on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint | Corbus Pharmaceuticals | Research Agreement | United States |
| 18-Jan-18 | Biocon | $0 | To develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide. | Novartis | Partnership | India |
| 17-Jan-18 | Aeterna Zentaris Inc | $128 | To carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. | Strongbridge Biopharma plc | Licensing Agreement | United States |
| 10-Jan-18 | Syndax Pharmaceuticals Inc | $0 | To Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer | Roche | Clinical Collaboration | United States |
| 26-Jan-18 | Unipharm | $0 | To acquire a range of over-the-counter (OTC) medicines, Reinforce Strong Patient Focused Business in Russia | Takeda Pharmaceutical Company | Acquisition | Uzbekistan |
| 04-Jan-18 | Generation Bio | $0 | Developing GeneWave™ - A Breakthrough Platform for Re-Dosable Gene Therapy | Atlas Venture | Launch & Partnerships | United States |
| 09-Jan-18 | Boehringer Ingelheim | $0 | Two companies have entered into a commercial supply agreement for tislelizumab, BeiGene’s investigational anti-PD-1 antibody | BeiGene | Commercialization Agreement | Germany |
| 31-Jan-18 | TransPerfect Life Sciences | $0 | To support clinical trials and product development for the biopharmaceutical industry, Trial Interactive e-clinical and eTMF technology | Advarra | Partnership | United States |
| 30-Jan-18 | CorePharma | $0 | It provides us with a strong and reputable manufacturing infrastructure and an ideal location with headquarters in Middlesex | Impax Laboratories Inc | Acquisition | United States |
| 30-Jan-18 | Boston University School of Medicine | $0 | To Study the Effects of Alzheimer's Disease-associated Genetic Variants on Brain | Eisai Co., Ltd. | Research Agreement | United States |
| 30-Jan-18 | Porton Pharma Solutions | $0 | To expands the reach of our offerings to provide fully integrated API and drug product development and manufacturing solutions to our clients for seamless advancement of their programs from discovery to clinical development | BioDuro LLC | Cooperation Agreement | China |
| 29-Jan-18 | Prime Therapeutics | $0 | Outcomes-Based Contract for Jardiance®(empagliflozin) | Boehringer Ingelheim | Contract Agreement | United States |
| 26-Jan-18 | Sandoz | $0 | ANDA Portfolio to build a robust pipeline and commercialize quality drug candidates in China, including entecavir, an antiviral medication used in the treatment of hepatitis B viral infection (“HBV”) | CASI Pharmaceuticals | Acquisition | United States |
| 23-Jan-18 | ChemDiv Inc | $0 | To extending it into finding potent anti-infective drug candidates & to deliver a pipeline of novel high-quality hit series in the area of infectious diseases | Johnson & Johnson | Collaboration | United States |
| 19-Jan-18 | Eisai Co | $0 | For potential anticancer agent E7046 prostaglandin E2 (PGE2)receptor type EP4 antagonist | Adlai Nortye Biopharma | Licensing Agreement | Japan |
| 19-Jan-18 | Tabuk Pharmaceuticals | $0 | To commercialize and distribute Ivy ODF in the Kingdom of Saudi Arabia, the Gulf and Levant area | Red OTC Development GmbH | Licensing Agreement | Saudi Arabia |
| 17-Jan-18 | Undisclosed | $0 | To Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System | Relmada Therapeutics | Acquisition | |
| 16-Jan-18 | Compass Therapeutics | $0 | For the semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling of a therapeutic targeting solid tumors. Semi-mechanistic PK/PD models will be developed for mouse, cynomolgus monkey, and human species | Applied BioMath | Collaboration | United States |
| 23-Jan-18 | Valeant Pharmaceutical | $0 | Begins Promotion of SPRIX®( ketorolac tromethamine) Nasal Spray | Egalet Corporation | Partnership | United States |
| 23-Jan-18 | ABL Bio | $0 | To Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies & to Manufacture Clinical Material for SillaJen's JX-970 | SillaJen Inc | Collaboration | France |
| 10-Jan-18 | Roche | $0 | To Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer | Syndax Pharmaceuticals | Clinical Collaboration | United States |
| 10-Jan-18 | Syapse | $0 | To Advance Precision Medicine in Oncology, Companies work jointly to develop software products and analytics solutions | Roche | Collaboration | United States |
| 31-Jan-18 | Syapse | $0 | Partnership will democratize access to clinical trials and help community health systems find and enroll eligible patients at unprecedented scale | Medidata | Partnership | United States |
| 08-Jan-18 | GE Healthcare | $0 | To jointly develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualised treatment options for cancer and critical care patients | Roche | Partnership | United States |
| 08-Jan-18 | Livongo Health | $0 | To study real-world evidence and develop new insights to reduce the burden on people living with diabetes | Eli Lilly and Company | Collaboration | United States |
| 08-Jan-18 | Intec Pharma | $0 | To explore using the Accordion Pill platform for a proprietary Novartis compound | Novartis | Collaboration | Israel |
| 04-Jan-18 | Pfizer Inc. | $0 | Focused on optimizing BLI’s proprietary BeaconTM Optofluidic platform with the goal of helping to accelerate Pfizer’s monoclonal antibody (mAb) discovery and gene editing workflows | Berkeley Lights, Inc | Collaboration | United States |
| 03-Jan-18 | Corsair Pharma | $0 | To Advance Novel Treprostinil Prodrugs | United Therapeutics Corporation | Collaboration | United States |
| 02-Jan-18 | BASES Pharmaceutical | $0 | These new assets and expertise complement the rest of our forecasting offerings | ZS Associates | Acquisition | United States |
| 02-Jan-18 | PharmaMar | $0 | For the marine-derived anticancer drug Aplidin® (plitidepsin) in Israel and the territory known as the Palestinian Authority | Megapharm Ltd | Licensing Agreement | Spain |
| 29-Jan-18 | Japan Tobacco Inc | $0 | Acquires rights to small molecule potassium channel inhibitors | Metrion Biosciences | Acquisition | Japan |
| 26-Jan-18 | Concept Life Sciences Group | $0 | Acquisition increases Concept’s global reach and supports growth strategy | Spectris plc | Acquisition | United Kingdom |
| 15-Jan-18 | Tsing Hua Testing & Analysis | $0 | Tsing Hua provides a comprehensive suite of testing services for wastewater, drinking water, ground water, fuel gas, ambient air, noise, soil and waste to a broad range of customers in Taiwan | Eurofins Scientific | Acquisition | Taiwan |
| 25-Jan-18 | Eurofins Scientific | $0 | Selcia provides Eurofins with an entry into the custom radiolabelling and innovative pre-clinical, integrated drug discovery services markets, both exciting new business streams for Eurofins offering significant growth potential | Selcia Limited | Acquisition | Luxembourg |
| 25-Jan-18 | UCL Great Ormond Street Institute of Child Health | $0 | To Develop Novel Gene Therapies for Blood-based Disorders | Synpromics | Partnership | United Kingdom |
| 23-Jan-18 | Mydent International Enterprises Corp | $0 | The DEFEND brand has developed a reputation for high quality at great value that resonates well with clinicians and dental organizations around the world | Young Innovations | Acquisition | United States |
| 23-Jan-18 | Solid Form Solutions Ltd | $0 | Combination Strengthens CDMO’s Early Phase Drug Development Offering | Avista Pharma Solutions | Acquisition | Scotland |
| 23-Jan-18 | TP3 Global | $0 | To expand worldwide presence and strengthen product portfolio | Softbox | Acquisition | United Kingdom |
| 22-Jan-18 | BioCryst Pharmaceuticals | $0 | To form a new enterprise focused on the development and commercialization of medicines to serve more patients suffering from rare diseases | Idera Pharmaceuticals | Merger Agreement | United States |
| 22-Jan-18 | Elion Labs | $0 | To Further Expand Industry-Leading Biophysical and Analytical Characterization Capabilities | KBI Biopharma | Acquisition | United States |
| 16-Jan-18 | Arno Therapeutics | $0 | The Acquisition of Apristor™ (Onapristone XR), an Investigational Phase 2 Drug for Metastatic Breast Cancer | Context Therapeutics | Acquisition | United States |
| 12-Jan-18 | DrugScan Inc | $0 | To lead the way on the front lines of the opioid crisis here and across the nation | ACM Global Laboratories (Rochester Regional Health) | Acquisition | United States |
| 16-Jan-18 | Maine Biotechnology Services (MBS) | $0 | The addition of over 80 new antibodies to its growing product portfolio, as well as custom antibody development services | BBI Solutions | Acquisition | United States |
| 08-Jan-18 | Accurate Medical Therapeutics | $0 | Acceleration of the interventional radiology strategy | Guerbet | Acquisition | Israel |
| 08-Jan-18 | Cork (Luxcel Biosciences ) | $0 | This acquisition expands Agilent's cell analysis portfolio with the addition of easy-to-use assay kits that are compatible with industry standard plate-readers | Agilent Technologies | Acquisition | Ireland |
| 08-Jan-18 | Merus | $0 | To develop and commercialize in China three bispecific antibodies utilizing Merus’ proprietary Biclonics® technology platform in the area of immuno-oncology. | Simcere Pharmaceutical Group | Collaboration | The Netherlands |
| 08-Jan-18 | Radiant Genomics | $0 | The addition brings Radiant Genomics’ leading-edge metagenomic technologies and accompanying genetic libraries to Zymergen’s core platform, accelerating Zymergen’s ability to identify and commercialize novel molecules used in a range of industries | Zymergen | Acquisition | United States |
| 05-Jan-18 | Vita Liberata | $0 | Adds Leading, All-Natural Product Line in Sunless Tanning to Crown’s Dermatology Portfolio | Crown Laboratories Inc & Hildred Capital Partners LLC | Acquisition | Ireland |
| 03-Jan-18 | Angiochem Inc | $0 | To develop and commercialize ANG1005 in China for treatment of patients with leptomeningeal carcinomatosis from breast cancer | Xinogen | Licensing Agreement | Canada |
| 04-Jan-18 | Zyga Technology | $0 | Acquisition Expands Spine Franchise Portfolio and Accelerates Growth Potential; Zyga Technology Provides Innovative SImmetry® Sacroiliac Joint Fusion System | RTI Surgical Inc | Acquisition | United States |
| 04-Jan-18 | Rocket Pharmaceuticals | $0 | It focus on advancing a pipeline of gene therapy programs targeting rare and undertreated diseases. | Inotek Pharmaceuticals Corporation | Merger Agreement | United States |
| 03-Jan-18 | Array BioPharma | $0 | To develop, manufacture and commercialise varlitinib | ASLAN Pharmaceuticals | Acquisition | United States |
| 03-Jan-18 | Viamet Pharmaceuticals | $0 | To advance the clinical development of VT 1161 for the treatment of RVVC and Onychomycosis | NovaQuest Capital Management LLC | Acquisition | United States |
| 03-Jan-18 | Glen Research Corporation (“Glen Research”) | $0 | Glen Research will continue its focus on superior customer service as part of the Maravai portfolio | Maravai LifeSciences & GTCR | Acquisition | United States |
| 09-Jan-18 | Inovio Pharmaceuticals | $0 | Advances development of Inovio’s ASPIRE™ (Antigen SPecific Immune REsponses) immunotherapy platform as a foundation for novel combination regimen approaches | The Parker Institute | Clinical Collaboration | United States |
| 18-Jan-18 | Pfizer Inc. | $0 | To Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma | Gilead Sciences | Clinical Collaboration | United States |
| 09-Jan-18 | Dracen Pharmaceuticals | $0 | To develop its platform of anticancer therapies | The Johns Hopkins University (Baltimore) & The Institute of Organic Chemistry and Biochemistry (Prague) | Licensing Agreement | United States |
| 18-Jan-18 | Bio-Pharm Inc | $0 | To expand the BPI facilities including R&D capabilities and will increase the number of product filings from BPI | Torrent Pharmaceuticals Limited | Acquisition | United States |
| 03-Jan-18 | Metanomics Health GmbH | $0 | To Create a New Global Leader in Metabolomics and Early Disease Detection | BIOCRATES Life Sciences AG | Acquisition | Germany |
| 14-Feb-18 | Nektar Therapeutics | $3,600 | To evaluate the full-potential of NKTR-214 plus Opdivo (nivolumab) across numerous tumors, based on promising early data from ongoing Phase 1/2 PIVOT clinical study | Bristol-Myers Squibb | Collaboration | United States |
| 18-Jan-18 | Sangamo Therapeutics | $3,150 | To Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer | Gilead Sciences | Collaboration | United States |
| 15-Feb-18 | Flatiron Health | $1,900 | To accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer | Roche | Acquisition | United States |
| 20-Feb-18 | Voyager Therapeutics | $1,200 | To Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases | AbbVie | Collaboration | United States |
| 09-Feb-18 | Pieris Pharmaceuticals | $1,200 | Pieris Pharmaceuticals entered into the collaboration with Seattle Genetics with the goal of developing multiple targeted bispecific immuno-oncology treatments for solid tumors and blood cancers. | Seattle Genetics | Collaboration | United States |
| 21-Feb-18 | CJ HealthCare | $1,200 | Kolmar Korea, which is the largest OEM manufacturer in the local cosmetics industry, is expected to beef up its medical cosmetics business based on the acquisition | Korea Kolmar | Acquisition | South Korea |
| 07-Feb-18 | Theravance Biopharma | $1,000 | Both Jointly Develop and Commercialize TD-1473, a Novel, Potent, Orally Administered and Intestinally Restricted pan-Janus Kinase (JAK) Inhibitor | Johnson & Johnson | Collaboration | Ireland |
| 20-Feb-18 | Wave Life Sciences Ltd. | $1,000 | To receive option to co-develop and co-commercialize investigational therapies in HD, ALS, FTD and SCA3 under a global 50:50 profit-split & receive right to license additional preclinical CNS programs | Takeda Pharmaceutical Company | Collaboration | United States |
| 13-Feb-18 | MPI Research | $800 | To enhance Charles River’s position as a leading global early-stage CRO by strengthening its ability to partner with clients across the drug discovery and development continuum | Charles River | Acquisition | United States |
| 12-Feb-18 | POXEL SA | $600 | For Development and Commercialization of Imeglimin in the U.S., Europe, and Additional Countries Worldwide | Roivant Sciences | Partnership | France |
| 01-Feb-18 | Moderna Therapeutics | $500 | The funding will help drive the company’s continued execution of its rapidly growing pipeline of 19 development candidates – including 10 programs in clinical trials | Abu Dhabi Investment Authority (ADIA) | Financing | United States |
| 21-Feb-18 | Viralytics | $394 | Proposed Acquisition of Viralytics Would Add Investigational Oncolytic Immunotherapy, CAVATAK ® , Supporting Merck’s Strategy to Broaden Its Pipeline with the Best Scientific Assets | Merck & Co. | Acquisition | Australia |
| 20-Feb-18 | Ionis Pharmaceuticals | $330 | Ionis Licences New Antisense Drug for Kidney Disease to AstraZeneca | AstraZeneca | Collaboration | United States |
| 14-Feb-18 | GNC Holdings | $300 | Hayao will also form a JV with GNC to make and distribute GNC supplements in China | Harbin Pharma | Investment | United States |
| 14-Feb-18 | TandemLife | $300 | Company will add advanced cardiopulmonary temporary support solutions to its portfolio | LivaNova | Acquisition | United States |
| 13-Feb-18 | TetraGenetics | $300 | TetraGenetics expertise and ideally suited to the capabilities of the TetraExpress™ platform technology. These programs build on TetraGenetics’ prior successes using the platform for the discovery of drug candidates targeting membrane proteins | Undisclosed | Collaboration | United States |
| 28-Feb-18 | Viela Bio | $250 | To create stand-alone company for early-stage inflammation and autoimmunity biologics | AstraZeneca | Financing | United States |
| 15-Feb-18 | Celularity | $250 | Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration | Celgene Corporation | Financing | United States |
| 28-Feb-18 | Novo Nordisk | $165 | To invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance. | Novo Nordisk | Investment | Denmark |
| 06-Feb-18 | ImmunoQure | $164 | Partnership for the development of an Interferon alpha human autoantibody | Servier | Partnership | Germany |
| 08-Feb-18 | Rani Therapeutics | $142 | Rani raises investment for manufacturing of a pill that replaces injections | GeneScience Pharmaceuticals | Financing | United States |
| 15-Feb-18 | Polyphor | $129 | To Develop and Commercialize Clinical Stage Candidate for Cystic Fibrosis and Other Pulmonary Diseases for POL6014 | Santhera Pharmaceuticals | Licensing Agreement | Switzerland |
| 21-Feb-18 | PROCEPT BioRobotics | $118 | Treatment of Benign Prostatic Hyperplasia | Viking Global Investors | Financing | United States |
| 15-Feb-18 | Oxford BioMedica | $105 | To use OXB’s LentiVector Enabled technology and access to its industrial-scale manufacturing technology | Bioverativ | Collaboration | United Kingdom |
| 12-Feb-18 | Avid Bioservices, Inc | $103 | Asset Assignment and Purchase Agreement for Avid's PS-Targeting Program Including Bavituximab | Oncologie, Inc. | Purchase Agreement | United States |
| 13-Feb-18 | Universal Cells | $103 | To fully utilize proprietary technology to produce pluripotent stem cells that have the potential to lower immunological rejection in numerous therapeutic areas | Astellas Pharma | Acquisition | United States |
| 27-Feb-18 | Generation Bio | $100 | To Advance Genewavetm Platform For Re-Dosable Gene Therapy | Fidelity Management | Investment | United States |
| 15-Feb-18 | BD (Becton, Dickinson and Company) | $100 | For Purchase of Divestment Assets, The assets acquired are soft tissue core needle biopsy products sold under the trade names of Achieve™ Programmable Automatic Biopsy System, Temno™ Biopsy System, Tru-Cut™ Biopsy Needles as well as Aspira® Pleural Effusion Drainage Kits, and the Aspira® Peritoneal Drainage System | Merit Medical Systems Inc | Investment | United States |
| 07-Feb-18 | Elastagen Pty Ltd | $95 | To Access Next Generation Injectable Portfolio & Clinical stage tropoelastin platform with potential applications in aesthetics, scar remodeling and surgical wound repair | Allergan plc | Acquisition | Australia |
| 27-Feb-18 | Surmodics | $92 | Companies to collaborate on product development, clinical trials and regulatory activities to obtain approval in U.S. and E.U. | Abbott | Clinical Collaboration | United States |
| 01-Feb-18 | AVROBIO, Inc | $60 | To Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic Diseases | Atlas Venture ; Syndicate | Series B Financing | United States |
| 28-Feb-18 | Inscripta | $56 | To accelerate development and commercialization of gene-editing tools — including enzymes, reagents, instrumentation, and software | Merieux Developpement and Paladin Capital Group | Series C Financing | France |
| 27-Feb-18 | Senti Biosciences | $53 | To Build the Future of Gene and Cell-Based Therapies | New Enterprise Associates | Series A Financing | United States |
| 21-Feb-18 | ORIC Pharmaceuticals | $50 | Proceeds will support advancement of ORIC-101 against treatment-resistant solid tumors and continued progress on mechanisms of resistance in cancer | Fidelity Management | Series C Financing | United States |
| 27-Feb-18 | Quentis Therapeutics | $48 | Role of small-molecule inhibitor of IRE1 alpha, a key ER stress pathway in Cancer Treatment | AbbVie | Series A Financing | United States |
| 20-Feb-18 | Tetraphase Pharmaceuticals, Inc. | $43 | Tetraphase and Everest will establish a joint steering committee to review and oversee all of Everest’s development and commercialization plans | Everest Medicines Limited | Licensing Agreement | United States |
| 14-Feb-18 | Ferring Biotech Centre | $32 | Ferring expands its capabilities in biologics through a new biotech centre & In addition to new biologics in reproductive medicine and women’s health, fertility treatment Rekovelle® (follitropin delta) will also be manufactured at the new centre | Ferring Pharmaceuticals | Investment | Switzerland |
| 01-Mar-18 | IQGEN Holdings LLC | $25 | The Vantage fund aims to invest in technology-driven healthcare companies in India and other Asian nations, founder and managing partner | Venture Capital | Investment | India |
| 28-Feb-18 | Revance Therapeutics | $25 | To Bring a Biosimilar to the Market for the development and commercialization of a proposed biosimilar to BOTOX® (onabotulinumtoxinA) | Mylan N.V. | Collaboration | United States |
| 27-Feb-18 | Neurona Therapeutics | $24 | Transplantation of selected neurons to treat intractable neurological diseases | The Column Group | Series A Financing | United States |
| 08-Feb-18 | UCB (Syndesi Therapeutics) | $21 | To develop a series of molecules that modulate the protein SV2A, which is involved in synaptic transmission | Johnson & Johnson | Partnership | Belgium |
| 26-Feb-18 | Exelixis, Inc. | $20 | Submission of Regulatory Filing for Esaxerenone (CS-3150) in Japan | Daiichi Sankyo | Collaboration | United States |
| 15-Feb-18 | ABAC Therapeutics | $20 | To Develop Therapeutic Solutions to Fight Antibiotic-Resistant Bacteria | Pontifax | Series A Financing | Spain |
| 26-Feb-18 | Prokarium | $10 | For clinical development of revolutionary thermostable vaccines | Riyadh Valley Company (RVC) & Saudi, Swedish and Korean investors | Investment | United Kingdom |
| 15-Feb-18 | SMART Medical Systems Ltd | $8 | SMART's present financing will be used primarily to commercialize its G-EYE® product | Signet Healthcare Partners, a NY-based healthcare | Series B Financing | Israel |
| 12-Feb-18 | Avadel Pharmaceuticals | $8 | Under the terms of the licensing and development agreement, Avadel will develop and provide Cerecor with four stable product formulations utilizing its LiquiTime™ and Micropump® platforms. | Cerecor, Inc. (CERC) | Asset Acquisition | Ireland |
| 23-Feb-18 | Aakar Innovations, Saathi Eco Innovations etc (India) | $8 | Support of women’s empowerment, sexual and reproductive health and rights, water and sanitation, and global mental health in India | Govt.of Canada through Global Affairs Canada | Investment | India |
| 28-Feb-18 | Synergy Pharmaceuticals | $5 | Acquires Exclusive Canadian Rights to FDA-Approved TRULANCE® | Cipher Pharmaceuticals | Acquisition | United States |
| 28-Feb-18 | Randob Labs | $4 | To divest the brand Balmex | Moberg Pharma AB | Investment | United States |
| 15-Feb-18 | Solaris Nutraceuticals | $2 | Building the largest medical cannabis greenhouse southern hemisphere facility | Federal Department of Innovation, Industry & Science | Grants & Awards | Australia |
| 26-Feb-18 | Amarantus | $2 | Phase 2b Eltoprazine program for Parkinson's disease levodopa-induced dyskinesia (PD-LID) and Cutanogen Corporation's pending pivotal trial in Pediatric Severe Burns | Dominick & Dickerman LLC | Financing | United States |
| 05-Feb-18 | SCIEX | $0 | Devised an isotopic methodology in which all biological molecules are uniformly and randomly labeled to create informative isotopic patterns that are readily discriminated from artifacts | IROA Technologies LLC | Marketing Agreement | United States |
| 08-Feb-18 | Massachusetts General Hospital | $0 | Progression of neurofibrillary tangles (NFTs) and Parkinson's Disease tau protein | Cerveau Technologies, Inc | Research Agreement | United States |
| 22-Feb-18 | Preora Healthcare | $0 | To Bring Novel Intracellular Visualization Technology to Cancer Diagnostic Market | Planet Innovation | Collaboration | United States |
| 22-Feb-18 | Evinance Innovation, Inc | $0 | This acquisition expands the capabilities of Varian's 360 Oncology™ care management platform by tightly integrating clinical workflow, decision support, and adherence tracking based on leading cancer care guidelines | Varian | Acquisition | Canada |
| 22-Feb-18 | Bridgemedica, LLC | $0 | To further diversify portfolio and expand into markets that we believe have strong growth potential | NN, Inc. | Acquisition | United States |
| 21-Feb-18 | ATUM | $0 | To Accelerate Drug Discovery ATUM licenses Company’s Leap-In Transposase® Technology | Just Biotherapeutics | Licensing Agreement | United States |
| 20-Feb-18 | Melinta Therapeutics | $0 | Eurofarma Laboratórios is Melinta’s commercialization and distribution partner for all countries in South and Central America and the Caribbean, including Argentina. The proposed indication for delafloxacin in Argentina is for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI). | Eurofarma Laboratorios | Commercialization Agreement | Brazil |
| 20-Feb-18 | Orthotaxy | $0 | To Develop Next-Generation Robotic-Assisted Surgery Platform in Orthopaedics | Johnson & Johnson | Acquisition | France |
| 20-Feb-18 | Pure Applied Sciences | $0 | To acquire Pure Applied Sciences and its brand PureOrganix, a line of organic and pure cannabis oils and related accessories | Cannabis Strategic Ventures, In | Acquisition | United States |
| 15-Feb-18 | ABAC Therapeutics | $18 | ABAC develops new targeted antibiotics for patients with severe infections | Debiopharm Innovation Fund | Acquisition | Spain |
| 13-Feb-18 | Apex Resource Technologies | $0 | Medical Plastics Leader Enhances Specialty Products Portfolio & Design Engineering Through Acquisition | Spectrum Plastics Group | Acquisition | United States |
| 09-Feb-18 | Vaxart, Inc. | $0 | To develop oral recombinant vaccines as tablets | CAS Group | Merger Agreement | South Africa |
| 12-Feb-18 | Kerafast Inc. | $0 | Absolute Antibody specializes in the sequencing, engineering and recombinant production of antibodies. Their catalog offers more than 3,400 recombinant antibodies in new engineered versions, absolutely defined at the amino acid level to ensure batch-to-batch reproducibility. | Absolute Antibody Ltd. | Merger Agreement | United States |
| 08-Feb-18 | Corpus Medical | $0 | Combining Advanced Catheter Technology Design and Development with Confluent Medical Manufacturing Capabilities | Confluent Medical Technologies | Acquisition | United States |
| 07-Feb-18 | IncoCare Gunhild Vieler GmbH | $0 | To further strengthen its position in Germany. Together, Coloplast and IncoCare will bring innovative products and services to more users across Germany | Coloplast | Acquisition | Germany |
| 06-Feb-18 | Texas A&M University Health Science Center College of Medicine Institute for Regenerative Medicine | $0 | The Agreement for Alzheimer’s Research & Celltex acquires intellectual property license, signs multi-year research study with Texas A&M Health Science Center | Celltex Therapeutics Corporation | Licensing Agreement | United States |
| 01-Feb-18 | NCPC GeneTech Biotechnology | $0 | To export CJ-40001, a second-generation erythropoietin (EPO) biosimilar | CJ HealthCare | Contract Agreement | China |
| 01-Feb-18 | Sanofi | $0 | To develop, manufacture, and commercialize Leukine (sargramostim) | Partner Therapeutics | Acquisition | France |
| 01-Feb-18 | Amgen | $0 | Agreement for the cholesterol-lowering drug, Repatha® (evolocumab) | Abarca | Contract Agreement | United States |
| 22-Feb-18 | Biohaven Pharmaceutical Holding Company | $0 | To provide Catalent’s Zydis® ODT (orally disintegrating tablet) fast-dissolving formulation for the development of Biohaven’s lead calcitonin gene-related peptide (CGRP) receptor antagonist product candidate, rimegepant | Catalent U.K. Swindon Zydis Limited | Licensing Agreement | United States |
| 17-Feb-18 | Health Elite Club Limited ("HECL") | $0 | To Distribute ZanthoSyn® in China | Cardax, Inc | Purchase Agreement | Hong Kong |
| 13-Feb-18 | GC Pharma | $0 | To Develop and Commercialise GCC-4401C, an Investigational Anticoagulant | Lee's Pharmaceutical (HK) Limited | Licensing Agreement | South Korea |
| 13-Feb-18 | Shanghai Dahua Pharmaceutical Co.,Ltd. | $0 | To increase access to contraceptive implants | DKT International | Partnership | China |
| 13-Feb-18 | BC Platforms | $0 | It will be using its technology solutions and research platform, including BCRQUEST.COM, to study data in cardiovascular diseases | Pfizer Inc. | Partnership | Switzerland |
| 08-Feb-18 | MKO Global Partners | $0 | Company expands presence in the pharma consulting space with the addition of pricing and payer strategy services | Two Labs | Partnership | United States |
| 01-Feb-18 | AstraZeneca | $0 | Immuno Oncology Clinical Trial Collaboration & it will evaluate combination of SNDX-6352 with durvalumab (ImfinziTM) in solid tumors | Syndax Pharmaceuticals | Collaboration | United Kingdom |
| 14-Feb-18 | Roivant Sciences | $0 | A proposal to jointly develop Arbutus’ nucleic acid delivery platform based on its Lipid Nanoparticle (LNP) technology and GalNAc technology (collectively, Delivery Technologies) through a new company that would jointly own, manage, and develop the Delivery Technologies | Arbutus Biopharma Corporation | Exclusivity Agreement | Switzerland |
| 08-Feb-18 | Fujifilm Corporation | $0 | To develop regenerative medicine therapies using cardiomyocytes derived from iPSC for the treatment of heart failure | Takeda Pharmaceutical Company | Collaboration | Japan |
| 21-Feb-18 | Arix Bioscience plc | $0 | To develop and commercialise innovative therapies. | Ipsen | Partnership | United Kingdom |
| 22-Feb-18 | SCD Pharmaceuticals | $0 | To develop, manufacture and market a portfolio of ophthalmic products in the U.S. and Canada | Glenmark Pharmaceuticals | Collaboration | United States |
| 22-Feb-18 | Kallyope Inc. | $0 | To Advance Programs Targeting the Gut-Brain Axis | Euclidean Capital and Two Sigma Ventures | Series B Financing | United States |
| 21-Feb-18 | Johnson & Johnson | $0 | To establish a collaborative laboratory focused on 3D bioprinting | AMBER | Collaboration | United States |
| 22-Feb-18 | Regulus Therapeutics Inc. | $0 | Agreement follows the recent opening of WuXi STA’s oligonucleotide R&D labs in China and the USAn | WuXi AppTec | Collaboration | United States |
| 20-Feb-18 | Atomo Diagnostics | $0 | To create next generation FebriDx® tests that are anticipated to transform the diagnosis of febrile acute respiratory infections (ARI) at the point-of-care | RPS Diagnostics | Partnership | Australia |
| 22-Feb-18 | Babraham Research Campus in Cambridge (UK) | $0 | To accelerate its AI-enabled drug development | BenevolentAI | Acquisition | United Kingdom |
| 26-Feb-18 | AGC Biologics | $0 | To continue development and advancement of CB 2679d through the clinic | Catalyst Biosciences | Manufacturing Investment | United States |
| 26-Feb-18 | Selexis | $0 | To Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates | Xencor | Expanded Partnership | Switzerland |
| 26-Feb-18 | Biosensorix | $0 | To Develop Next-Generation Point-of-Care Diagnostics Based on Research at Ben Gurion University | BGNTechnologies | Collaboration | Singapore |
| 26-Feb-18 | Bioventus | $0 | To Co-Develop Next Generation Bone Allograft | LifeLink Tissue Bank | Partnership | United States |
| 28-Feb-18 | Likarda | $0 | To offer online access to its innovative 3D compound screening and assay development services to scientists around the globe. | Science Exchange | Partnership | United States |
| 27-Feb-18 | Cipla | $0 | For the promotion and sale of tocilizumab and the 2nd brand of bevacizumab (Avastin) | Roche | Partnership | India |
| 27-Feb-18 | Aldeyra Therapeutics | $0 | To Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases | Johnson & Johnson | Research Agreement | United States |
| 27-Feb-18 | Elekta | $0 | To continue development of clinical protocols for MR-linac technology | Memorial Sloan Kettering Cancer Center (MSK) | Collaboration | Sweden |
| 27-Feb-18 | Janssen Pharmaceuticals | $0 | For access to TESARO's ZEJULA® (niraparib), an orally administered poly (ADP-ribose) polymerase (PARP) inhibitor undergoing clinical development, PARP inhibitor niraparib for Sierra's Phase 1b/2 combination trial with Chk1 inhibitor SRA737 | Sierra Oncology, Inc. | Supply Agreement | United States |
| 26-Feb-18 | Edico Genome | $0 | To Streamline Clinical Next-Generation Sequencing Workflows | InterSystems | Partnership | United States |
| 27-Feb-18 | Kaken Pharmaceutical Co., Ltd | $0 | To Develop And Commercialize New Chemical Entity For Psoriasis | Valeant Pharmaceuticals | Licensing Agreement | Japan |
| 26-Feb-18 | Bavarian Nordic | $0 | To evaluate CV301 in combination with durvalumab in colorectal and pancreatic cancers | Georgetown University Dr. Michael Pishvaian | Collaboration | Denmark |
| 26-Feb-18 | Roche | $0 | To Evaluate Combination of ZEJULA® (Niraparib) and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder Cancer | TESARO, Inc. | Collaboration | United States |
| 27-Feb-18 | Naveos | $0 | Acquisition expands suite of revenue integrity solutions for healthcare providers and adds market-leading capabilities in government reimbursement | Revint Solutions | Acquisition | United States |
| 26-Feb-18 | MHM Services | $0 | To Expand National Footprint In Correctional Healthcare Sector | Centene Corporation | Acquisition | United States |
| 28-Feb-18 | Acorda Therapeutics, Inc | $0 | Developing therapies which improve the lives of people with neurological disorders- Parkinson’s disease and multiple sclerosis | Scopia Capital Management | Collaboration | United States |
| 27-Feb-18 | Median Technologies | $0 | Median and CMIC will leverage complementary expertise to help biopharmaceutical companies accelerate oncology drug development in Japan, China and East Asia. | CMIC HOLDINGS Co., Ltd. | Collaboration | United States |
| 26-Feb-18 | Tissue Regenix | $0 | Companies collaborate to educate surgeons and hospitals about the safety, comfort and performance advantages of DermaPure® biologic for pelvic floor surgery | ARMS Medical | Collaboration | United States |
| 26-Feb-18 | CellSystems GmbH | $0 | For AlphaSTEM™ Naïve Stem Cell Culture System | Minerva Biotechnologies | Distribution Agreement | Germany |
| 21-Feb-18 | Tolmar Australia Pty Limited | $0 | Exclusive distribution rights for the oncology medication Eligard® | Mundipharma | Acquisition | Australia |
| 08-Feb-18 | Q Biomed Inc | $0 | For a Novel Companion Biomarker for Monitoring Glaucoma , Under the agreement granting the exclusive right to license the technology, | Washington University in St. Louis | Option Agreement | United States |
| 27-Feb-18 | Mindstrong Health | $0 | Development of digital biomarkers for selected mental health conditions | Takeda Pharmaceutical Company | Partnership | United States |
| 26-Feb-18 | Elsevier | $0 | To Enable Deeper Research into Traditional Chinese Medicine | Beijing University of Chinese Medicine | Collaboration | United States |
| 08-Feb-18 | HOVON | $0 | To Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Chemotherapy | GlycoMimetics, Inc | Clinical Collaboration | The Netherlands |
| 13-Feb-18 | Medidata | $0 | To include Edge eTMF and Edge CTMS | Aperio or iNNO Clinical | Expansion | United States |
| 20-Feb-18 | MAB Discovery GmbH (MABD) | $0 | To develop novel antibody therapeutics based on MABD’s unique discovery platform | Cullinan Oncology, LLC | Collaboration | Germany |
| 19-Feb-18 | OncoLens | $0 | Enabling patients to enroll in trials faster, obtain treatment at local community cancer centers | Optimal Research | Collaboration | United States |
| 15-Feb-18 | BullFrog AI | $0 | To Improve Antipsychotic Drug Selection | Lieber Institute for Brain Development | Collaboration | United States |
| 06-Feb-18 | Charles River | $0 | To Accelerate Drug Discovery and Development | HemaCare | Partnership | United States |
| 08-Mar-18 | Express Scripts | $67,000 | To create an expanded portfolio of health services with greater choice, alignment and value across a proven services platform | Cigna Corporation | Acquisition | United States |
| 27-Mar-18 | Novartis | $13,000 | Agreement with Novartis to buyout Novartis’ 36.5% stake in the Consumer Healthcare Joint Venture for $13 billion (£9.2 billion) | GlaxoSmithKline | Joint Venture | Switzerland |
| 08-Mar-18 | Eisai Co | $5,760 | Companies to Jointly Develop and Commercialize LENVIMA, as Monotherapy and in Combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.’s KEYTRUDA® (pembrolizumab) for Multiple Cancer Types | Merck & Co. | Collaboration | Japan |
| 16-Mar-18 | Johnson & Johnson | $2,100 | Johnson & Johnson today announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately $2.1 billion, subject to customary adjustments. | Platinum Equity | Acquisition | United States |
| 15-Mar-18 | Ionis Pharmaceuticals | $1,700 | Collaboration advances commercial readiness for planned mid-2018 inotersen launch, positioning Akcea to successfully launch two drugs for significant rare diseases this year | Akcea Therapeutics | Licensing Agreement | United States |
| 16-Mar-18 | Prexton Therapeutics BV | $1,113 | Foliglurax is a first-in-class treatment, which entered clinical phase II testing in Parkinson’s disease in July 2017. | H. Lundbeck A/S | Acquisition | The Netherlands |
| 29-Mar-18 | Irvine Scientific Sales Company (ISUS) , IS Japan (ISJ) | $800 | The expected synergies are 1) the further expansion of the contact development and manufacturing business for biopharmaceuticals, 2) the acceleration of research and development in the area of regenerative medicine, and 3) the further expansion of reagent business. | FUJIFILM Corporation | Acquisition | United States |
| 12-Mar-18 | Nutranext | $700 | Nutranext’s products include multivitamins under the Rainbow Light® brand, the No. 2 vitamin brand in the natural channel1; specialty minerals under the Natural Vitality® brand, the No. 1 anti-stress and sleep brand in the natural channel2; and supplements for hair, skin and nails under the Neocell® brand. | The Clorox Company | Acquisition | United States |
| 16-Mar-18 | Pfizer Inc. | $590 | PF-04958242 is an AMPA receptor potentiator designed to facilitate neurotransmission for cognitive impairment associated with schizophrenia (CIAS). | Biogen | Asset Acquisition | United States |
| 28-Mar-18 | CureTech | $553 | InSight will make an immediate payment of $50 million which will be used to fund development of CureTech’s immunotherapy candidate, which is currently geared towards the treatment of diffuse intrinsic pontine glioma (DIPG), a rare variety of brain tumour. | InSight Biopharmaceuticals Ltd. | Acquisition | Israel |
| 26-Mar-18 | National Institute For Bioprocessing Research & Training | $462 | Shire, the Ireland-domiciled pharma group that specialises in rare diseases, has signed a training deal with the National Institute of Bioprocessing Research and Training (Nibrt) in Dublin. The €375 million investment will create the company’s European quality control hub for its biologics portfolio. | Shire PLC | Collaboration | Ireland |
| 21-Mar-18 | NxThera | $406 | Acquisition expands portfolio with minimally invasive treatment option for patients with benign prostatic hyperplasia. NxThera developed and commercialized, in the United States (U.S.) and Europe, the Rez?m® system which is a minimally invasive therapy in a growing category of treatment options for men with symptoms arising from BPH | Boston Scientific | Acquisition | United States |
| 26-Mar-18 | Arena Pharmaceuticals, Inc. | $406 | Arena anticipates using the net proceeds from the offering for the clinical and preclinical development of drug candidates, including its planned Phase 3 programs for etrasimod for the treatment of ulcerative colitis and ralinepag for the treatment of pulmonary arterial hypertension, for general corporate purposes, including working capital and costs associated with manufacturing services, and for capital expenditures. | Undisclosed | IPO | United States |
| 05-Mar-18 | Heidelberg Pharma AG | $334 | The collaboration will combine Magenta’s stem cell platform with proprietary antibodies across up to four exclusive targets with Heidelberg Pharma’s proprietary ATAC (Antibody Targeted Amanitin Conjugates) platform. | Magenta Therapeutics | Collaboration | Germany |
| 29-Mar-18 | C4X Discovery | $294 | C4X Discovery signs licensing agreement with Indivior for addiction programme worth up to $294 million. | Indivior PLC | Licensing Agreement | United Kingdom |
| 08-Mar-18 | Advanced Analytical Technologies, Inc. | $250 | This acquisition will enhance Agilent's existing expertise and technology, while giving customers a more comprehensive set of solutions. AATI solutions are comprised of instruments, software and consumables aimed at simplifying complex workflows. | Agilent Technologies | Acquisition | United States |
| 12-Mar-18 | Cogentix Medical Inc. | $214 | The addition of Cogentix’s suite of technology will significantly expand LABORIE’S therapeutic offering, thereby providing customers and their patients with comprehensive, clinically-relevant solutions along the disease treatment continuum. | LABORIE Medical Technologies | Acquisition | Canada |
| 01-Mar-18 | Helix OpCo LLC | $200 | Helix operates one of the world’s largest CLIA-and-CAP-accredited Next Generation Sequencing laboratories. Powered by Illumina technologies, Helix uses its proprietary Exome+ assay to sequence each customer’s 20,000 protein-coding genes as well as additional information-rich areas identified by Helix’s scientific team. | DFJ Growth | Series B Financing | United States |
| 20-Mar-18 | Prothena Corporation plc | $150 | Collaboration focuses on preclinical programs targeting proteins implicated in several neurodegenerative diseases, including tau, TDP-43 and an undisclosed third target | Celgene Corporation | Collaboration | Ireland |
| 27-Mar-18 | Homology Medicines | $150 | Homology Medicines is based on an important scientific discovery – a novel set of adeno-associated virus vectors derived from human hematopoietic stem cells (AAVHSCs) that are designed to precisely and efficiently deliver genetic medicines in vivo either through gene therapy or gene editing. | Undisclosed | IPO | Germany |
| 07-Mar-18 | STEMCELL Technologies | $142 | STEMCELL Technologies has signed an exclusive license with Indiana University Innovation and Commercialization Office for patented rights to groundbreaking inner ear organoid technologies. | Indiana University Innovation and Commercialization Office | Licensing Agreement | Canada |
| 20-Mar-18 | Oxford Nanopore | $140 | Funding will support new manufacturing facility, commercial expansion, and development of new innovative products. | GIC, CCB International, Hostplus | Financing | United Kingdom |
| 19-Mar-18 | Arcus Biosciences, Inc. | $138 | Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist and an anti-PD-1 antibody, both of which are in Phase 1 trials, as well as a small molecule inhibitor of CD73 and an anti-TIGIT antibody, which are in IND-enabling studies. | Undisclosed | IPO | United States |
| 07-Mar-18 | Aptose Biosciences | $125 | Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced an exclusive global license agreement that provides OHM Oncology with the rights for the development, manufacture and commercialization of APL-581, as well as related molecules from Aptose’s dual bromodomain and extra-terminal domain motif (BET) protein and kinase inhibitor program. Aptose will retain reacquisition rights to certain mole | OHM Oncology | Licensing Agreement | United States |
| 21-Mar-18 | TCR2 Therapeutics | $125 | Proceeds will support clinical development of lead program TC-210 and expansion of the multi-format TRuC™-T cell pipeline in solid tumors and blood cancers | MPM Capital; 6 Dimensions Capital, | Series B Financing | United States |
| 29-Mar-18 | Hua Medicine | $117 | The financing is expected to fully fund the Company through completion of its two Phase 3 trials and commercial launch in China for Dorzagliatin (HMS5552), a new first-in-class, 4th-generation glucokinase activator (GKA) that treats the impaired blood glucose sensor function, and thereby seeks to address the underlying cause of Type 2 diabetes. | Blue Pool Capital, Alibaba Group | Series D Financing | China |
| 05-Mar-18 | Vividion Therapeutics | $101 | Collaboration utilizes Vividion’s unique proteome-wide ligand and target discovery platform. | Celgene Corporation | Research Agreement | United States |
| 01-Mar-18 | Rubius Therapeutics | $100 | Proceeds from the financing will be used to accelerate the development of the Company’s portfolio of RCTs™ towards clinical proof-ofconcept, and to enhance its manufacturing capacity and capabilities. | Flagship Pioneering | Financing | United States |
| 02-Mar-18 | Tricida, Inc. | $100 | This financing provides Tricida with significant financial flexibility as it continues the development of TRC101 for the treatment of metabolic acidosis in chronic kidney disease patients | Hercules Capital, Inc. | Financing | United States |
| 27-Mar-18 | Nabriva Therapeutics | $95 | As part of the license agreement, Nabriva has granted a Roivant subsidiary an exclusive license to develop and commercialize lefamulin in the greater China region, specifically the People’s Republic of China, Hong Kong, Macau, and Taiwan. | Roivant Sciences | Financing | Ireland |
| 15-Mar-18 | Ideaya Biosciences | $94 | Proceeds to advance multiple synthetic lethality and immuno-oncology therapies into the clinic | Nextech Invest | Series B Financing | United States |
| 02-Mar-18 | JW Therapeutics | $90 | By combining Juno’s world-class technology and platform with WuXi AppTec Group’s local expertise, R&D and manufacturing platform, and broader partnerships, JW Therapeutics has successfully initiated the development of its first CD19-directed investigational therapy, JWCAR029 (a CAR-T therapy being studied for the treatment of B-cell malignancies initially focusing on relapsed and refractory DCBCL). | Temasek, Sequoia Capital China, YuanMing Capital etc. | Series A Financing | China |
| 20-Mar-18 | Tempus | $80 | The additional funds will be used to further grow and scale the company’s clinical and molecular analytic platform. | New Enterprise Associates | Series D Financing | United States |
| 08-Mar-18 | Prevail Therapeutics | $75 | Prevail’s lead program, PR001, will be developed for a genetic subset of Parkinson’s disease and other mechanistically-related disorders. | OrbiMed | Series A Financing | United States |
| 09-Mar-18 | Humacyte, Inc. | $75 | The funding is expected to support Humacyte’s ongoing HUMANITY study, the company’s pivotal Phase III study assessing the human acellular vessel (HAV), or HUMACYL®, as a conduit for hemodialysis in patients with end-stage renal disease who are not candidates for fistula placement. | PointState Capital | Series C Financing | United States |
| 08-Mar-18 | Evotec AG | $74 | Evotec-led platform expands current initiatives to accelerate research and development (“R&D”) of novel anti-infectives. Sanofi to licence more than 10 infectious disease R&D assets to evotec while retaining option rights for development and commercialisation. | Sanofi | Research Agreement | Germany |
| 28-Mar-18 | Tempest Therapeutics | $70 | Proceeds from the Series B financing will support the advancement of lead program TPST-8844 into the clinic in the next 12 months as well as advancement of at least two other programs into the clinic shortly thereafter. | Versant Ventures, F-Prime Capital, Quan Capital | Series B Financing | United States |
| 13-Mar-18 | Crinetics Pharmaceuticals | $64 | Crinetics Pharmaceuticals plans to use the proceeds to fund the continuing development of CRN00808, an oral nonpeptide somatostatin agonist for the potential treatment of acromegaly, to develop additional new targeted therapeutics for endocrine disorders and endocrine related cancers, and for general corporate purposes. | Perceptive Advisors | Series B Financing | United States |
| 22-Mar-18 | Rheos Medicines | $60 | Founded by luminaries in the field of immunometabolism, Rheos aims to identify mechanisms and discover medicines that tune metabolic pathways in immune cells. Company’s therapeutics will focus on well-defined patient subsets in heterogeneous diseases including autoimmunity, inflammation and in immuno-oncology applications. | Third Rock Ventures | Series A Financing | United States |
| 12-Mar-18 | BioXcel Therapeutics | $60 | The proceeds from the IPO will be used to fund the Phase II testing of the company's two most advanced drug candidates: BXCL501 and BXCL701. About $42 million of the total amount raised through the IPO will be used for Phase II research, with much of the remaining money slated to be used for working capital and for general corporate purposes, according to the company's SEC filing. | Undisclosed | IPO | United States |
| 27-Mar-18 | Singlera Genomics | $60 | The funds will help Singlera expand the development and commercialization of its non-invasive genetic tests for early-stage cancer detection and clinical validation studies. | Green Pine Capital Partners | Series A Financing | United States |
| 02-Mar-18 | CARsgen Therapeutics | $60 | The funds will be used in support of Investigational New Drug submissions of several CAR-T therapeutics and Next-generation CAR-T research. | Undisclosed | Financing | China |
| 09-Mar-18 | Xeris Pharmaceuticals | $55 | The proceeds from the two financings will help accelerate the development of additional product candidates applying Xeris’ ready-to-use glucagon to intermittent and chronic-use indications that require administration over a longer period. | Silicon Valley Bank | Series C Financing | United States |
| 13-Mar-18 | Bristol-Myers Squibb | $55 | As part of the restructuring, Biohaven will pay BMS an upfront payment of $50 million in return for a low single digit reduction in the royalties payable on net sales of rimegepant and a mid-single digit reduction in the royalties payable on net sales of BHV-3500. | Biohaven Pharmaceutical Holding Company Ltd. | Licensing Agreement | United States |
| 19-Mar-18 | Unity Biotechnology | $55 | Proceeds from this financing will be used to advance the company's lead senolytic drug candidates into human clinical trials. UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. | EcoR1 Capital Fund, 6 Dimensions Capital | Series C Financing | United States |
| 23-Mar-18 | Mabion S.A. | $51 | Mabion intends to use the net proceeds from the financing to cover the cost of the expansion of production capacity in Konstantynów ?ódzki, Poland and costs and expenses related to the development and commercialization of Mabion CD20. | European Bank For Reconstruction And Development (EBRD) And PFR Life Science Sp. Z O.O. | Private Placement | Poland |
| 20-Mar-18 | CASI Pharmaceuticals | $50 | The Company is working on its portfolio of 29 abbreviated new drug applications (ANDAs) (including 25 FDA-approved and 4 pending approval) that were recently acquired from Sandoz, and will continue to further expand the pipeline as part of their mission to bring innovative and high-quality medicines to the market. | ETP Global Fund LP, IDG-Accel China Growth Fund III | Private Placement | United States |
| 14-Mar-18 | Foghorn Therapeutics | $50 | Company’s Proprietary Gene Traffic ControlTM Product Platform Provides a New Way to Think About Treating Disease | Flagship Pioneering | Launch & Partnerships | United States |
| 26-Mar-18 | Adagene Inc. | $50 | The funds from this round of financing will be used to advance novel antibody therapeutics into human trials across the globe. The antibodies discovered from our Dynamic Precision Library [DPL] platform enable translational research of our therapeutic leads on the intact immune system of highly predictive preclinical models. | Sequoia China | Series C Financing | China |
| 22-Mar-18 | CBT Pharmaceuticals | $47 | The agreement gives CBT exclusive world-wide development and commercialization rights to a novel, recombinant, human monoclonal antibody which targets a differentiated epitope on the cytotoxic T-lymphocyte antigen-4 (CTLA-4) molecule. Binding of this antibody to CTLA-4 blocks the interaction of CTLA-4 with its ligands CD80/CD86 thus allowing the cytotoxic T cells to function actively. | Crown Bioscience | Licensing Agreement | United States |
| 12-Mar-18 | TAE Life Sciences | $40 | TAE Life Sciences is leveraging TAE Technologies’ unique accelerator-based neutron beam technology for Boron Neutron Capture Therapy (BNCT) to bring promising treatment potential for head and neck, glioblastoma multiforme (GBM) and other cancers that are difficult or impossible to treat with traditional methods. | Neuboron Medtech, Ltd., ARTIS Ventures | Series A Financing | United States |
| 22-Mar-18 | Dracen Pharmaceuticals | $40 | Dracen will develop its glutamine antagonists both in single agent settings as well as in combination with immune checkpoint inhibitors such as anti-PD-1 and anti-PD-L1. The goal of these therapies is to increase the number of responders to anti-cancer therapy and extend survival; and potentially, to provide anti-tumor responses in areas currently evading immuno-oncology approaches. | Deerfield Management | Series A Financing | United States |
| 06-Mar-18 | Themis Bioscience | $38 | First major investment by Coalition for Epidemic Preparedness Innovations (CEPI) to advance vaccine development and manufacturing on two of CEPI’s highest priority infectious diseases. | Coalition for Epidemic Preparedness Innovations (CEPI) | Financing | Norway |
| 01-Mar-18 | Finch Therapeutics | $36 | The combination of the two biotechs also came with new support from Crestovo supporter Chris Shumway of Shumway Capital, who helped bring the syndicate together. | Takeda Pharmaceutical Company | Series B Financing | United States |
| 09-Mar-18 | Adagene Inc. | $36 | The collaboration with WuXi Biologics will support supply of Adagene’s products for clinical trials under Investigational New Drug (IND) applications in both China and United States. | WuXi AppTec | Research Agreement | China |
| 16-Mar-18 | Bavarian Nordic | $36 | With funding from the DoD, Bavarian Nordic will utilize its proprietary MVA-BN® platform to develop a vaccine against various strains of the virus, for which there is currently no preventative vaccine treatment available. | United States Department of Defense (DoD) | Partnership | Denmark |
| 05-Mar-18 | ViewPoint Therapeutics | $35 | ViewPoint plans to use the proceeds of the financing to develop its lead product candidate, VP1-001, through clinical proof-of-concept studies in patients with cataracts and presbyopia. In addition, ViewPoint anticipates that the proceeds will also allow the Company to advance second-generation compounds from its ongoing medicinal chemistry efforts. | The Rise Fund | Series B Financing | United States |
| 08-Mar-18 | Gelesis | $30 | The proceeds from the financing will be used to support commercial-stage manufacturing, product launch preparations, company operations, and clinical advancement of the Company’s pipeline of additional product candidates for gastrointestinal disorders, including Type 2 diabetes and non-alcoholic steatohepatitis/non-alcoholic fatty liver disease (NASH/NAFLD). The Company also plans to submit Gelesis100 for regulatory approvals in the US and Europe in 2018. | PureTech Health | Financing | United States |
| 13-Mar-18 | AbCellera Biologics Inc. | $30 | Under DARPA’s Pandemic Prevention Platform (P3) program, AbCellera will apply its state-of-the art capabilities in human antibody discovery and immune profiling to establish rapid countermeasures for viral pandemics. | Defense Advanced Research Projects Agency (DARPA) | Collaboration | Canada |
| 06-Mar-18 | Science 37 | $29 | This three-year commitment will enable a more extensive portfolio of trials powered by the Network Oriented Research Assistant (NORA®), Science 37’s proprietary technology platform that enables patients to participate in clinical research regardless of their geographical location using mobile devices and telemedicine services. | Novartis | Partnership | United States |
| 08-Mar-18 | Cyteir Therapeutics | $29 | Financing proceeds will be used to advance RAD51 inhibitor toward the clinic and expand small-molecule synthetic lethality platform for oncology and autoimmune diseases. | DROIA Oncology Ventures | Series B Financing | United States |
| 13-Mar-18 | Kiadis Pharma N. V. | $29 | This €23.4 million private placement will fund the Company into H2 2019 and thus well beyond potential EU approval and into potential European launch of ATIR101™. | Undisclosed | Private Placement | The Netherlands |
| 06-Mar-18 | Medeon Biodesign, Inc. | $20 | Under the terms of the agreement, Terumo will pay US$20 million upfront and additional payments based on the achievement of future specific development milestones. It will be funded through cash on hand. | Terumo Corporation | Asset Acquisition | Taiwan |
| 20-Mar-18 | Cipher Pharmaceuticals | $20 | The Canadian business portfolio to be acquired by Cipher includes commercial and pipeline hospital products administered in the acute care setting, including Brinavess® (vernakalant IV), Aggrastat® (tirofiban hydrochloride), Xydalba™ (dalbavancin hydrochloride), andnTrevyent® a drug device combination that delivers treprostinil, the world's leading treatment for pulmonary arterial hypertension. | Cardiome Pharma Corporation | Partnership | Canada |
| 13-Mar-18 | Escalier Biosciences | $19 | Escalier is developing both topical and oral ROR?t drug candidates for psoriasis and expects to be in the clinic with its topical compound in mid 2018. | Forbion | Series B Financing | The Netherlands |
| 15-Mar-18 | Minakem SAS | $18 | The €14.5M ($18M) investment from parent company Minafin is the first of this magnitude. It will enable the company to set up a new production line, increasing production capacity by 28m3. | Minafin S.A. | Financing | France |
| 06-Mar-18 | 23Mofang (Chengdu 23 Magic Cube Biotechnology Co., Ltd.) | $16 | Maximum cost for the 23Mofang test is $158. Its biochip, which was co-developed with Thermo Fisher Scientific, tests for as many as 300 medical conditions. Proceeds from the newest round of financing will be used to enlarge its test centre, boost research and development of products, and expand further into the market. | Matrix Partners China | Series B Financing | China |
| 15-Mar-18 | Arbor Biotechnologies, Inc. | $16 | Arbor’s discovery platform employs a diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – to curate and mine the natural genetic diversity for impactful peptides, proteins, and enzymes. This approach enables systematic and high-throughput discovery of new molecules for improving human health and sustainability. | ARCH Venture Partners, Faridan Ventures | Series A Financing | United States |
| 01-Mar-18 | Cullgen | $15 | Cullgen's new drug discovery platform has the advantage of accelerating NCEs into clinical development in a cost and time efficient manner to benefit patients. Initial drug discovery programs will focus on oncology and expand into areas such as inflammatory and autoimmune diseases. | GNI Group Ltd. | Seed Financing | United States |
| 06-Mar-18 | Oxford Vacmedix | $13 | Spun out by Oxford University Innovation in 2012, OVM is commercialising research led by Dr Shisong Jiang, ndeveloped as a partnership between Oxford University’s Department of Oncology and the Medical Research nCouncil’s Weatherall Institute of Molecular Medicine, also based in Oxford. The technology uses the novel, proprietary platform of recombinant overlapping peptides to design and develop therapeutic cancer vaccines and diagnostics with the potential for increased efficacy. | Cancer Rop Co | Series A Financing | United Kingdom |
| 29-Mar-18 | Swift Medical | $12 | Already the market frontrunner with more than 1,000 facilities signed up across North America, Swift forges further ahead with plans to expand to every wound patient’s bedside. | Data Collective | Series A Financing | Canada |
| 19-Mar-18 | twoXAR, Inc. | $10 | The proceeds will be used to build the company’s drug pipeline through partnerships and accelerate preclinical development of existing candidates. | SoftBank Ventures, Andreessen Horowitz Bio Fund, OS Fund | Series A Financing | United States |
| 05-Mar-18 | Veru Inc. | $10 | Under the terms of the deal, Veru received $10 million at closing and may receive an additional $2 million upon potential signing of tenders for FC2 Female Condom® product with two large international customers, subject to minimum units ordered. | SWK Holdings | Financing | United States |
| 02-Mar-18 | City of Hope National Medical Center | $6 | The City of Hope trial hopes to address this unmet medical need for adults with severe SCD. | California Institute for Regenerative Medicine | Grants & Awards | United States |
| 15-Mar-18 | Parachute Health | $6 | Health Tech Platform Revolutionizes $50 Billion Medical Equipment Industry by Reducing Hospital Costs & Improving Patient Care | Greater New York Hospital Association Ventures, Loeb Holding Corporation | Seed Financing | United States |
| 13-Mar-18 | Immutep S.A. | $5 | Immutep Limited has announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the combination of Immutep’s lead immunotherapy product candidate eftilagimod alpha (“efti” or “IMP321”) with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a new clinical trial that will evaluate the combination in several solid tumours. | Merck & Co. | Clinical Collaboration | Australia |
| 05-Mar-18 | MicuRx Pharmaceutical Inc | $5 | The new agent MRX-8 is designed to overcome the limiting nephrotoxicity of current polymyxins. Current preclinical data demonstrated its high efficacy, with the reduced nephrotoxicity as well as attenuated acute or neuromuscular toxicity, when compared to existing polymyxin drugs. | Combating Antibiotic Resistant Bacteria Accelerator (CARB-X) | Financing | United States |
| 13-Mar-18 | Immuron Limited | $4 | Immuron has received a number of recent offers for financial support following the release of the Company’s positive top-line results of its IMM-124E Phase II Non-Alcoholic Steatohepatitis (NASH) clinical study. | Joseph Gunnar & Co., LLC | Private Placement | Australia |
| 28-Mar-18 | BriaCell Therapeutics Corp. | $3 | The Company will use the proceeds from the Note Offering and the Non-Brokered Unit Offering, which includes investments from leading U.S. biotech funds such as Brio Capital Master Fund Ltd., Efrat Investments LLC and Mario Family Partners LP, to: (i) finance the Company’s Phase-2a clinical trial; (ii) to finance the Company’s pursuit of other research opportunities; and (iii) for working capital and general corporate purposes. | Brio Capital Master Fund Ltd., | Purchase Agreement | Canada |
| 14-Mar-18 | PixCell Medical | $3 | |
Market Place
Excel Download